Brooklyn Beneish M Score

BTX
 Stock
  

USD 0.54  0.02  3.85%   

This module uses fundamental data of Brooklyn Immunotherapeuti to approximate the value of its Beneish M Score. Brooklyn Immunotherapeuti M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis.
  
Refresh
Brooklyn Immunotherapeuti Total Debt is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Total Debt of 2.72 Million in 2021. Debt Current is likely to rise to about 437.2 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (966.8 K) in 2022. Brooklyn Immunotherapeuti Current Ratio is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Ratio of 5.10 in 2021. Debt to Equity Ratio is likely to rise to 4.30 in 2022, whereas Return on Investment is likely to drop (24.25)  in 2022.
At this time, it appears that Brooklyn Immunotherapeuti is an unlikely manipulator. The earnings manipulation may begin if Brooklyn Immunotherapeuti's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Brooklyn Immunotherapeuti executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Brooklyn Immunotherapeuti's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-17.15
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables1.16Focus
Asset Quality0.28Focus
Expense Coverage0.9Focus
Gross Margin Strengs1.02Focus
Accruals Factor0.9Focus
Depreciation Resistance0.99Focus
Net Sales Growth1.07Focus
Financial Leverage Condition1.03Focus

Brooklyn Immunotherapeuti Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Brooklyn Immunotherapeuti's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues19.2 M17.8 M
Notably Up
Decreasing
Slightly volatile
Selling General and Administrative Expense14.2 M14.7 M
Sufficiently Down
Decreasing
Slightly volatile
Net Cash Flow from Operations(24.1 M)(23.5 M)
Fairly Down
Decreasing
Slightly volatile
Depreciation Amortization and Accretion471.1 K459 K
Fairly Up
Decreasing
Slightly volatile
Total Assets26.9 M32.4 M
Significantly Down
Increasing
Slightly volatile
Investments1.2 M1.1 M
Significantly Up
Increasing
Slightly volatile
Investments Non Current1.2 M1.1 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net3.3 M3.2 M
Slightly Up
Decreasing
Stable
Trade and Non Trade Receivables979.9 K786.6 K
Fairly Up
Increasing
Very volatile
Total Liabilities20.6 M25.9 M
Significantly Down
Increasing
Slightly volatile
Current Assets20.2 M18.8 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current12.2 M13.7 M
Fairly Down
Increasing
Slightly volatile
Current LiabilitiesM3.7 M
Significantly Up
Increasing
Very volatile
Liabilities Non Current24 M22.2 M
Significantly Up
Increasing
Slightly volatile
Total Debt3.8 M2.7 M
Significantly Up
Increasing
Slightly volatile
Debt Current437.2 K426 K
Fairly Up
Increasing
Stable
Debt Non Current2.6 M2.3 M
Moderately Up
Increasing
Slightly volatile
Operating Income(107.7 M)(105 M)
Fairly Down
Decreasing
Slightly volatile
Gross Margin0.570.56
Fairly Up
Decreasing
Slightly volatile

Brooklyn Immunotherapeuti Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Brooklyn Immunotherapeuti's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Brooklyn Immunotherapeuti in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Brooklyn Immunotherapeuti's degree of accounting gimmicks and manipulations.

About Brooklyn Immunotherapeuti Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Operating Expenses

113.27 Million

Share
Brooklyn Immunotherapeuti Operating Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Operating Expenses of 104.98 Million in 2021

Brooklyn Immunotherapeuti Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Brooklyn Immunotherapeuti. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Revenues22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Total Assets16.57 M14.86 M14.12 M13.78 M32.43 M26.9 M
Current Assets9.64 M6.79 M6.07 M1.73 M18.77 M20.25 M
Assets Non Current6.93 M8.08 M8.05 M12.04 M13.66 M12.15 M
Total Liabilities11.03 M7.95 M9.03 M25.36 M25.93 M20.6 M
Current Liabilities10.75 M4.02 M6.09 M3.12 M3.68 M4.96 M
Total Debt5.41 M3.81 M6.08 M2.9 M2.72 M3.79 M
Debt Current5.24 M1.04 M3.17 M799 K426 K437.21 K
Debt Non Current172 K2.77 M2.91 M2.1 M2.3 M2.61 M
Operating Income(1.4 M)203 K(1.77 M)(7.21 M)(104.98 M)(107.75 M)

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  265.78  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
29.7 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.